Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 16, 2017. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It reports a specific securities transaction:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of shares via dividend re-investment.
- Volume: 395 shares.
- Price: £15.2748 per share.
- Date: October 12, 2017.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations. It documents a routine acquisition of shares by Dr. S. Dexter, a PCA of Dr. P. J. T. Vallance (President, R&D), following the dividend payment on October 12, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. It is strictly a regulatory disclosure of a specific share transaction.
Investor Verification Points
- Verify the identity of Dr. S. Dexter and their relationship to Dr. P. J. T. Vallance.
- Confirm the dividend re-investment plan details applicable to the October 12, 2017 payment.
- Note that this filing does not reflect broader company performance; refer to Form 20-F for financial results.